Logo image of PTRA

PROTERRA INC (PTRA) Stock Fundamental Analysis

NASDAQ:PTRA - Nasdaq - US74374T1097 - Common Stock - Currency: USD

0.067  -0.02 (-25.56%)

After market: 0.065 0 (-2.99%)

Fundamental Rating

2

PTRA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 129 industry peers in the Machinery industry. PTRA has a bad profitability rating. Also its financial health evaluation is rather negative. PTRA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

PTRA had negative earnings in the past year.
In the past year PTRA has reported a negative cash flow from operations.
PTRA Yearly Net Income VS EBIT VS OCF VS FCFPTRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -100M -200M -300M

1.2 Ratios

PTRA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTRA Yearly ROA, ROE, ROICPTRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 -10 -20 -30 -40

1.3 Margins

PTRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTRA Yearly Profit, Operating, Gross MarginsPTRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 0 -20 -40 -60 -80 -100

2

2. Health

2.1 Basic Checks

PTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PTRA has more shares outstanding
PTRA has a worse debt/assets ratio than last year.
PTRA Yearly Shares OutstandingPTRA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 50M 100M 150M 200M
PTRA Yearly Total Debt VS Total AssetsPTRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 200M 400M 600M 800M

2.2 Solvency

PTRA has an Altman-Z score of -2.67. This is a bad value and indicates that PTRA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.67, PTRA is doing worse than 90.63% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that PTRA is not too dependend on debt financing.
PTRA's Debt to Equity ratio of 0.00 is amongst the best of the industry. PTRA outperforms 85.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.67
ROIC/WACCN/A
WACC6.89%
PTRA Yearly LT Debt VS Equity VS FCFPTRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 200M -200M 400M 600M

2.3 Liquidity

PTRA has a Current Ratio of 1.39. This is a normal value and indicates that PTRA is financially healthy and should not expect problems in meeting its short term obligations.
PTRA's Current ratio of 1.39 is on the low side compared to the rest of the industry. PTRA is outperformed by 82.03% of its industry peers.
PTRA has a Quick Ratio of 1.39. This is a bad value and indicates that PTRA is not financially healthy enough and could expect problems in meeting its short term obligations.
PTRA's Quick ratio of 0.76 is on the low side compared to the rest of the industry. PTRA is outperformed by 81.25% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 0.76
PTRA Yearly Current Assets VS Current LiabilitesPTRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 200M 400M 600M 800M

4

3. Growth

3.1 Past

PTRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -194.37%.
Looking at the last year, PTRA shows a very strong growth in Revenue. The Revenue has grown by 29.59%.
EPS 1Y (TTM)-194.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.04%
Revenue 1Y (TTM)29.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.95%

3.2 Future

The Earnings Per Share is expected to grow by 20.03% on average over the next years. This is a very strong growth
PTRA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.82% yearly.
EPS Next Y-20.84%
EPS Next 2Y29.75%
EPS Next 3Y25.51%
EPS Next 5Y20.03%
Revenue Next Year47.51%
Revenue Next 2Y52.46%
Revenue Next 3Y59.79%
Revenue Next 5Y46.82%

3.3 Evolution

PTRA Yearly Revenue VS EstimatesPTRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
PTRA Yearly EPS VS EstimatesPTRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1 -1.5

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTRA. In the last year negative earnings were reported.
Also next year PTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTRA Price Earnings VS Forward Price EarningsPTRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTRA Per share dataPTRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PTRA's earnings are expected to grow with 25.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.75%
EPS Next 3Y25.51%

0

5. Dividend

5.1 Amount

PTRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PROTERRA INC

NASDAQ:PTRA (8/16/2023, 8:17:12 PM)

After market: 0.065 0 (-2.99%)

0.067

-0.02 (-25.56%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)08-09 2023-08-09/amc
Earnings (Next)N/A N/A
Inst Owners0.16%
Inst Owner Change0%
Ins Owners60.57%
Ins Owner Change0%
Market Cap15.26M
Analysts78.33
Price Target3.73 (5467.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-295.67%
Min EPS beat(2)-295.67%
Max EPS beat(2)-295.67%
EPS beat(4)0
Avg EPS beat(4)-166.66%
Min EPS beat(4)-295.67%
Max EPS beat(4)-98.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-10.08%
Min Revenue beat(2)-10.19%
Max Revenue beat(2)-9.97%
Revenue beat(4)1
Avg Revenue beat(4)-3.32%
Min Revenue beat(4)-10.19%
Max Revenue beat(4)16.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.58%
EPS NY rev (1m)0%
EPS NY rev (3m)-88.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB 0.06
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS1.5
BVpS1.17
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 265.8%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 0.76
Altman-Z -2.67
F-Score3
WACC6.89%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-194.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.04%
EPS Next Y-20.84%
EPS Next 2Y29.75%
EPS Next 3Y25.51%
EPS Next 5Y20.03%
Revenue 1Y (TTM)29.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.95%
Revenue Next Year47.51%
Revenue Next 2Y52.46%
Revenue Next 3Y59.79%
Revenue Next 5Y46.82%
EBIT growth 1Y-59.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.14%
EBIT Next 3Y35.23%
EBIT Next 5Y26.57%
FCF growth 1Y-137.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-134.92%
OCF growth 3YN/A
OCF growth 5YN/A